UFT経口投与による血中および膀胱腫瘍組織内5-FU濃度の検討

Abstract

膀胱腫瘍10例に対しUFT 1日 600 mg, 連日1週間の経口投与を行い, その血清, 正常膀胱粘膜および膀胱腫瘍組織内のFT, 5-FU, Uracilの濃度をそれぞれ測定した.1) FT濃度は血清7.721±4.652 μg/mlに対し, 膀胱粘膜3.748±2.527 μg/g, 膀胱腫瘍組織4.377±2.605 μg/gと各間に差はなかった.2) 5-FU濃度は血清0.017±0.016 μg/ml, 膀胱粘膜0.045±0.025 μg/gと低値を示したのに対し, 腫瘍内5-FU濃度は血清に比べ有意(P<0.05)に高い0.182±0.169 μg/gを示し, 腫瘍/血清比は10.7, また腫瘍/膀胱粘膜比は4.0であった.3) Uracil濃度も腫瘍内において血清および正常膀胱粘膜に比べ, 有意(それぞれP<0.01, P<0.05)に高値を示した.4)以上からUFTは膀胱腫瘍において腫瘍組織内5-FU濃度を選択的に上昇させ, 膀胱腫瘍に対する有用な治療薬剤と考えられた

The concentration of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT), 5-fluorouracil (5-FU) and uracil in blood, the bladder tumor tissue and the bladder mucosa after oral administration of 600 mg per day of UFT for 7 consecutive days was examined in 10 cases of bladder tumors. The concentration of FT and uracil in the tumor tissue did not significantly increase as compared with that in the blood and the bladder mucosa. However, the concentration of 5-FU in the tumor tissue remarkably increased and was 10.7 and 4 times as much as that in the blood and the bladder mucosa, respectively. These results show that administration of UFT meaningfully increases the 5-FU content in bladder tumors and enhances the antitumor activity.